<html xmlns="http://www.w3.org/1999/xhtml"><body><table class="table"><caption /><tr><th class="cell">Patients with MS on natalizumab </th><th class="cell">n = 20 </th></tr><tr><td class="cell">Time on natalizumab prior to study</td><td class="cell">16.6 ± 10.9 (2.8– 41.3)</td></tr><tr><td class="cell">entry (months)</td><td class="empty"></td></tr><tr><td class="cell">Age (years)</td><td class="cell">38.5 ± 7.4 (22.9– 55.1)</td></tr><tr><td class="cell">Women</td><td class="cell">n = 14 (70%)</td></tr><tr><td class="cell">Clinical course</td><td class="empty"></td></tr><tr><td class="cell">Relapsing– remitting MS</td><td class="cell">n = 18 (90%)</td></tr><tr><td class="cell">Progressive forms of MS^{∗}</td><td class="cell">n = 2 (10%)</td></tr><tr><td class="cell">Brain gadolinium-enhancing</td><td class="cell">n = 2 (10%)</td></tr><tr><td class="cell">lesions present</td><td class="empty"></td></tr><tr><td class="cell">Disease duration (years)^{†}</td><td class="cell">9.7 ± 4.3 (1.9– 20.2)</td></tr><tr><td class="cell">Expanded Disability Status Scale</td><td class="cell">2.3 ± 2.0 (0– 6.5)</td></tr><tr><td class="cell">score</td><td class="empty"></td></tr><tr><td class="cell">Timed 25-foot walk (s)</td><td class="cell">6.1 ± 3.4 (3.9– 17.0)</td></tr></table></body></html>